Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 459

Sort by

Sort Order Select

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

Blood (2019) 134 (Supplement_1): 763.

https://doi.org/10.1182/blood-2019-129097

Published: 2019

Journal Articles

The Cost of Healthcare for Pediatric Patients with Sickle Cell Disease

Maite E. Houwing, MD, Frederick Thielen, Anne P.J. de Pagter, MD PhD, Jan A Hazelzet, MD PhD, Hedwig Blommestein, Carin A. Uyl-de Groot, Marjon H. Cnossen, MD PhD

Blood (2019) 134 (Supplement_1): 1030.

https://doi.org/10.1182/blood-2019-130372

Published: 2019

Journal Articles

Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders

Luis E Malpica Castillo, MD, Shannon Palmer, MS, Anqi Zhu, MS, Allison Deal, MS, Sheh-Li Chen, PharmD, Stephan Moll, MD

Blood (2019) 134 (Supplement_1): 792.

https://doi.org/10.1182/blood-2019-121340

Published: 2019

Journal Articles

Anaemia in Labour: A Prospective Assessment of Women in Rivers State University Teaching Hospital, Nigeria

Paul L Kua, MBBS, FWACS, Hannah E Omunakwe, Afam C Okafor, BSc, MSc, George Monima Williams, MBBS

Blood (2019) 134 (Supplement_1): 4804.

https://doi.org/10.1182/blood-2019-127948

Published: 2019

Journal Articles

Characteristics and Financial Impact of Potentially Inappropriate Platelet Transfusion in the Inpatient Hospital Setting

Eric Mou, MD, Colin Murphy, MD, Jason Hom, MD, Lisa Shieh, MD, Neil Shah, MD

Blood (2019) 134 (Supplement_1): 2096.

https://doi.org/10.1182/blood-2019-125949

Published: 2019

Journal Articles

Thrombocytopenia and Anticoagulation: Impact of the ISTH SCC Anticoagulation Guidelines in Patients with Thrombocytopenia

Nicole Held, DO, Lisa Baumann Kreuziger, MD MS, Benjamin Jung

Blood (2019) 134 (Supplement_1): 2098.

https://doi.org/10.1182/blood-2019-127596

Published: 2019

Journal Articles

Late Effects Are Important Considerations in Initial Hodgkin Lymphoma Treatment Decision-Making According to Survivors

Anita J Kumar, MDMS, Rachel Murphy-Banks, MA, Ruth Ann Weidner, MBA, MRP, Susan K Parsons, MD MRP

Blood (2019) 134 (Supplement_1): 2137.

https://doi.org/10.1182/blood-2019-124481

Published: 2019

Journal Articles

Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease

Wally R Smith, MD, Daniel Sop, BS,MS, Shirley Johnson, BA, LSW, Thokozeni Lipato, MD, Mica Ferlis, ANP, Caitlin Mcmanus, ANP, Margaret Guy, MD, Sarah Hartigan, MD, Emily Holt, BS, Chantal McHenry, BS, John D. Roberts, MD

Blood (2019) 134 (Supplement_1): 2104.

https://doi.org/10.1182/blood-2019-130441

Published: 2019

Journal Articles

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Patrick Hagen, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD, Omar Davila, Mei-Jie Zhang, David H. Vesole, MD PhD, Scott E. Smith, MD PhD, Tulio E Rodriguez, MD, Patrick J. Stiff, MD

Blood (2019) 134 (Supplement_1): 2023.

https://doi.org/10.1182/blood-2019-124188

Published: 2019

Journal Articles

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Sandip Patel, MBBS, Tiffany George, MD, Tzu-Fei Wang, MD MPH, Sherry Mori Vogt, Pharm D, Edmund Folefac, MD, Ming Yin, MD

Blood (2019) 134 (Supplement_1): 3681.

https://doi.org/10.1182/blood-2019-130465

Published: 2019

Journal Articles

A Pilot Adult Sickle Cell Hematology Clinic in California's Inland Empire Improves Patient Outcome

Neha Chiruvolu, DO, Amie Patel, DO, Carolyn Rowley, PhD, Marsha J. Treadwell, PhD, Elliott P. Vichinsky, MD, Zahra Pakbaz, MD

Blood (2019) 134 (Supplement_1): 3470.

https://doi.org/10.1182/blood-2019-125160

Published: 2019

Journal Articles

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Katja Weisel, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo

Blood (2019) 134 (Supplement_1): 3480.

https://doi.org/10.1182/blood-2019-122232

Published: 2019

Journal Articles

Training Pediatric Hematologists / Oncologists for Capacity Building in Ethiopia

Daniel Hailu, MD, Haileyesus Adamu, MD, Diriba Fufa, MD, Doreen Karimi, MD, Thomas Alexander, MDMPH, Catherine Habashy, MD MPH, Amit Dotan, MD, Rabia M Wali, FCPS, MBBS, Prasanna N Kumar, MD, Miguel Bonilla, MD, Wondwessen Bekele, MD, Sheila Weitzman, MD, Julie Broas, JD, David N Korones, MD, Aziza T Shad, MD

Blood (2019) 134 (Supplement_1): 3423.

https://doi.org/10.1182/blood-2019-121796

Published: 2019

Journal Articles

An Institutional Retrospective Study on Recognizing the Delay in Multiple Myeloma Diagnosis

Nima Ghalehsari, MD, Pragnan Kancharla, MD MBBS, Neil S Nimkar, MD, Anita Mazloom, MD, Farah Ashraf, DO, Angelica Singh, MD, Mendel Goldfinger, MD

Blood (2019) 134 (Supplement_1): 3430.

https://doi.org/10.1182/blood-2019-127625

Published: 2019

Journal Articles

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Paul G. Richardson, MD, Alessandra Larocca, Xavier Leleu, MD PhD, Albert Oriol, MD, Agne Paner, MD, Paula Rodriguez Otero, Cyrille Touzeau, MD, Adrián Alegre Amor, MD, Christopher Maisel, MD, María-Victoria Mateos, MD PhD, Amitabha Mazumder, MD, Peter Strang, MD, Oskar Öhman, MSc, Johan Harmenberg, MD PhD, Stojan Zavisic, Joan Bladé, MD

Blood (2019) 134 (Supplement_1): 3487.

https://doi.org/10.1182/blood-2019-124832

Published: 2019

Journal Articles

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Andrew Sochacki, MD, Cosmin Adrian Bejan, PhD, Shilin Zhao, PhD, Travis Spaulding, MD, Shannon Stockton, MD, Alexander Silver, Dixon Dorand, MD PhD, Siwei Zhang, PhD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2959.

https://doi.org/10.1182/blood-2019-121513

Published: 2019

Journal Articles

Dysregulation of Hemostatic Biomarkers, Inflammatory Biomarkers, and Alteration of Cellular Indices As Predictors of Adverse Outcomes in Pulmonary Embolism Patients

Iman Darwish, Yevgeniy Brailovsky, DO, Amir Darki, MD MSc, Debra Hoppensteadt, PhD, Brett Slajus, Emily Bontekoe, Frank De Stefano, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 2408.

https://doi.org/10.1182/blood-2019-126876

Published: 2019

Journal Articles

Plasma Exchange in Thrombotic Microangiopathy: Is It Time Sensitive?

Sindhu Malapati, MD, Sunny R K Singh, MD, Rohit Kumar, MD, Jason Mouabbi, MD, Tarik Hadid, MD MS

Blood (2019) 134 (Supplement_1): 2353.

https://doi.org/10.1182/blood-2019-129375

Published: 2019

Journal Articles

Prenatal Hemoglobinopathy Screening Practices: Areas for Improvement

Scott Moerdler, MD, Ellen Fraint, MD, Ellen Silver, PhD, Siobhan M Dolan, MD, M.P.H., Kafui A Demasio, MD, M.P.H., Michael E. Roth, MD, Deepa Manwani, MD, Kerry A Morrone, MD

Blood (2019) 134 (Supplement_1): 2298.

https://doi.org/10.1182/blood-2019-126084

Published: 2019

NARROW

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

The Cost of Healthcare for Pediatric Patients with Sickle Cell Disease

Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders

Anaemia in Labour: A Prospective Assessment of Women in Rivers State University Teaching Hospital, Nigeria

Characteristics and Financial Impact of Potentially Inappropriate Platelet Transfusion in the Inpatient Hospital Setting

Thrombocytopenia and Anticoagulation: Impact of the ISTH SCC Anticoagulation Guidelines in Patients with Thrombocytopenia

Late Effects Are Important Considerations in Initial Hodgkin Lymphoma Treatment Decision-Making According to Survivors

Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

A Pilot Adult Sickle Cell Hematology Clinic in California's Inland Empire Improves Patient Outcome

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Training Pediatric Hematologists / Oncologists for Capacity Building in Ethiopia

An Institutional Retrospective Study on Recognizing the Delay in Multiple Myeloma Diagnosis

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Dysregulation of Hemostatic Biomarkers, Inflammatory Biomarkers, and Alteration of Cellular Indices As Predictors of Adverse Outcomes in Pulmonary Embolism Patients

Plasma Exchange in Thrombotic Microangiopathy: Is It Time Sensitive?

Prenatal Hemoglobinopathy Screening Practices: Areas for Improvement

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only